Hepatitis B: Working Towards a Cure.
First-line oral therapies for hepatitis B are effective at viral suppression, and treatment can lead to biochemical improvement and histologic regression. Unfortunately, recommended endpoints of treatment such as HBeAg loss and seroconversion may not be durable, with high rates of seroreversion, requiring monitoring, and unfortunately, low rates of  HBsAg loss/seroconversion. Additionally, meeting these endpoints requires years or even indefinite administration, leading to concerns regarding cost, side effects, and high rates of nonadherence. This article will review defined endpoints of therapy and their durability, the risks of long-term therapy, and the evolving new therapies aimed at a viral cure.
Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Bianca W
BW
Chang
Aung
A
Kaung
Lori
L
Robbins
Tram T
TT
Tran
D000998:Antiviral Agents / Q000627:therapeutic use*; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000097:blood; D006513:Hepatitis B e Antigens / Q000276:immunology; D006801:Humans; D000069078:Seroconversion; D016896:Treatment Outcome
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens